La vendita allo scoperto per Kamada dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Kamada. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Kamada (NASDAQ:KMDA) Azioni, Report sulle vendite allo scoperto

Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada Ltd

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA)))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a new plasma collection center in Houston, TX. The new 12,000 square foot center is operated by Kamada's wholly owned subsidiary, Kamada Plasma, and is planned to support over 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
"We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in Houston," said Amir London, Chief Executive Officer of Kamada. "The opening of this center is an important milestone in Kamada's development and vertical integration, expanding the collection capacity of specialty plasma for our internal use beyond our existing site in Beaumont, TX. The new center in Houston is expected to be one of the largest sites for specialty plasma collection in the U.S. and will also collect normal source plasma to be sold to third parties. We are especially grateful for the skilled and experienced team of plasma collection experts we have hired to lead the development and operations of our new center."
Kamada intends to submit to the FDA a prior approval supplement to Kamada Plasma's existing Biologics License Application (BLA) for the approval of the Houston site, as well as a plasma master file (PMF) to the European Medicines Agency (EMA), during the first half of 2025. The FDA and EMA's regulatory process for obtaining approval for plasma collection centers includes onsite inspection. During the review process, the company is authorized to collect plasma donations at the center. Kamada currently anticipates approval decisions within 9-12 months of submissions.
In addition to the new Houston center, the company has begun construction of its third plasma collection site in San Antonio, TX, which is expected to open during the first half of 2025. Each collection center is expected to contribute annual revenues of $8 million to $10 million in sales of normal source plasma at its full capacity.

Government

News

Regulations

KMDA

Kamada Expands US Plasma Operations with Houston Center, Plans FDA Submission

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

Guidance

Kamada Reiterates FY24 Revenue Guidance Of $158M - $162M (Est $159.60M) And Adjusted EBITDA Of $28M - $32M

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.06 by 33.33 percent. This is a 100 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $42.47 million which beat the analyst consensus estimate of $39.70 million by 6.99 percent. This is a 13.43 percent increase over sales of $37.44 million the same period last year.

Earnings

Earnings Beats

Kamada Q2 2024 GAAP EPS $0.08 Beats $0.06 Estimate, Sales $42.47M Beat $39.70M Estimate

Stifel analyst Annabel Samimy initiates coverage on Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy rating and announces Price Target of $18.

Initiation

Stifel Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $18

Kamada&nbsp;also increased adjusted EBITDA&nbsp;guidance&nbsp;to&nbsp;$28 million&nbsp;to&nbsp;$32 million&nbsp;from the initial&nbsp;guidance&nbsp;of&nbsp;$27 million&nbsp;to&nbsp;$30 million.
&quot;Importantly, we continue to pursue compelling new business development opportunities, leveraging our overall financial strength. These opportunities are expected to support continued growth at double-digit rates beyond 2024,&quot; the company said.

Kamada Boosts FY24 Revenue Guidance From $156M-$160M To $158M-$162M, Est $158.22M

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. The company reported quarterly sales of $37.736 million which missed the analyst consensus estimate of $38.007 million by 0.71 percent. This is a 22.88 percent increase over sales of $30.710 million the same period last year.

Earnings Misses

Kamada Q1 2024 GAAP EPS $0.04 Misses $0.06 Estimate, Sales $37.736M Miss $38.007M Estimate

&ldquo;Looking ahead, we anticipate continued momentum through 2024, with double-digit top- and bottom-line growth. Specifically, we are introducing full-year 2024 revenue guidance of $156 million to $160 million and adjusted EBITDA guidance of $27 million to $30 million. We maintain the financial strength and flexibility to accelerate the growth and profitability of our existing business beyond 2024 at double-digit rates and pursue compelling new business development opportunities, a process we are actively engaged in and that would further enhance our future growth,&rdquo; added&nbsp;Mr. London.
Fiscal Year 2024 Guidance 
Kamada expects to generate fiscal year 2024 total revenues in the range of $156 million to $160 million, and adjusted EBITDA in the range of $27 million to $30 million, representing double digit top- and bottom-line growth

Kamada Expects 2024 Revenues Of $156M-$160M Vs. $166.14M Consensus, And Sees Adjusted EBITDA In The Range Of $27M-$30M

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $0.05 by 80 percent. This is a 28.57 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $36.43 million which missed the analyst consensus estimate of $37.71 million by 3.39 percent. This is a 19.82 percent decrease over sales of $45.44 million the same period last year.

Kamada Q4 EPS $0.09 Beats $0.05 Estimate, Sales $36.43M Miss $37.71M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; CTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTS#NYSE">CTS</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
&bull; Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is likely to report quarterly earnings at $0.32 per share on revenue of $2.28 billion.
&bull; JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is likely to report quarterly earnings at $0.63 per share on revenue of $42.16 billion.
&bull; Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $326.63 million.
&bull; Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report earnings for its fourth quarter.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is estimated to report quarterly earnings at $0.67 per share on revenue of $2.27 billion.
&bull; Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $86.80 million.
&bull; VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $22.43 million.
&bull; Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is expected to report quarterly earnings at $2.83 per share on revenue of $1.43 billion.
&bull; Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $1.12 billion.
&bull; WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is likely to report quarterly loss at $0.23 per share on revenue of $19.86 million.
&bull; Yatsen Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YSG#NYSE">YSG</a>) is projected to report earnings for its fourth quarter.
&bull; iShares $ Short Duration Corp Bond UCITS ETF USD (Dist) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDIG#NASDAQ">SDIG</a>) is projected to report quarterly loss at $0.98 per share on revenue of $22.21 million.
&bull; InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $1.63 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $0.99 per share on revenue of $658.50 million.
&bull; Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $37.71 million.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is projected to report quarterly loss at $0.23 per share on revenue of $180 thousand.
&bull; Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $43.55 million.
&bull; Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is expected to report quarterly loss at $0.07 per share on revenue of $126.13 million.
&bull; Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $20.47 million.
&bull; NeueHealth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEUE#NYSE">NEUE</a>) is estimated to report quarterly loss at $4.16 per share on revenue of $283.44 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $2.44 billion.
&bull; EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is projected to report quarterly loss at $0.18 per share on revenue of $44.03 million.
&bull; Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is estimated to report quarterly loss at $2.01 per share on revenue of $55.25 million.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.01 per share on revenue of $8.42 million.
&bull; Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $1.75 million.
&bull; European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $54.08 million.
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is likely to report quarterly earnings at $0.15 per share on revenue of $579.42 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $7.87 billion.
&bull; Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $182.37 million.
&bull; Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter.
&bull; Trinity Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIN#NASDAQ">TRIN</a>) is estimated to report quarterly earnings at $0.54 per share on revenue of $46.42 million.
&bull; Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) is expected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $144.29 million.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Fortuna Silver Mines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $261.00 million.
&bull; Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) is estimated to report quarterly loss at $1.27 per share on revenue of $340 thousand.
&bull; Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $2.32 billion.
&bull; Global X Silver Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIL#NYSE">SIL</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $121.92 million.
&bull; Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $440.69 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.75 per share on revenue of $234.91 million.
&bull; Victoria&#39;s Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $2.09 billion.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is expected to report quarterly loss at $0.23 per share on revenue of $61.45 million.
&bull; KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $212.97 million.
&bull; Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly loss at $0.16 per share on revenue of $59.49 million.
&bull; GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $43.95 million.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $174.28 million.
&bull; IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is projected to report earnings for its second quarter.
&bull; FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is projected to report earnings for its fourth quarter.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $12.00 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is projected to report quarterly loss at $0.07 per share on revenue of $54.53 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is estimated to report earnings for its fourth quarter.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $76.22 million.
&bull; Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is likely to report quarterly loss at $0.09 per share on revenue of $421.19 million.
&bull; Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $280 thousand.
&bull; Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is expected to report quarterly loss at $0.12 per share on revenue of $70 thousand.
&bull; HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $339.52 million.
&bull; BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $123.75 million.
&bull; MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $18.14 million.
&bull; NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is estimated to report earnings for its fourth quarter.
&bull; Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $260.16 million.
&bull; Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $43.57 million.
&bull; OneSpan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSPN#NASDAQ">OSPN</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $58.26 million.
&bull; Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $84.14 million.
&bull; SilverCrest Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SILV#AMEX">SILV</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $44.09 million.
&bull; AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $7.93 million.
&bull; comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $97.69 million.
&bull; Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.00 million.
&bull; Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is projected to report earnings for its third quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $20.98 million.
&bull; Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is projected to report earnings for its fourth quarter.
&bull; Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter.
&bull; OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $37.73 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $40.28 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is projected to report earnings for its fourth quarter.
&bull; Airgain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRG#NASDAQ">AIRG</a>) is projected to report quarterly loss at $0.20 per share on revenue of $10.00 million.
&bull; Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is projected to report quarterly loss at $0.08 per share on revenue of $63.22 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $100.24 million.
&bull; TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $33.13 million.
&bull; CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $96.49 million.
&bull; Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $222.52 million.
&bull; Cyber Hornet S&amp;P 500 and Bitcoin 75/25 Strategy ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZZZ#NASDAQ">ZZZ</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $247.43 million.
&bull; Ellington Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $2.46 million.
&bull; Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is expected to report quarterly loss at $0.72 per share on revenue of $29.34 million.
&bull; Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $73.40 million.
&bull; Rush Street Interactive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSI#NYSE">RSI</a>) is likely to report quarterly loss at $0.03 per share on revenue of $178.56 million.
&bull; Hamilton Insurance Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HG#NYSE">HG</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.30 million.
&bull; Infinera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INFN#NASDAQ">INFN</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $437.34 million.
&bull; Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is estimated to report quarterly earnings at $1.60 per share on revenue of $94.75 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is expected to report quarterly loss at $0.43 per share on revenue of $15.45 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ADAP

AEYE

AIRG

AMPY

ARIS

BRCC

BWAY

CDXC

CMPO

CPSH

CULP

DSGX

EARN

EHAB

EVGO

EWCZ

FRPH

GENI

GENK

GROV

GWRS

HDSN

HIPO

HNST

HTOO

INFN

KEQU

KIDS

KLXE

LVLU

MDXH

NEUE

NEXN

NGMS

NSPR

OSPN

PowerShares Insured Municipal Bond Portfolio

REPX

REVG

SCOR

SDIG

SGHC

SILV

SLNG

SOHO

SPIR

TDCX

TLPH

TPVG

TRIN

UNFI

VBNK

VSCO

VSEC

XERS

YEXT

ZYME

Earnings Scheduled For March 6, 2024

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-06. Here's what investors need to know before the announcement.
Analysts estimate that Kamada will report an earnings per share (EPS) of $0.05. 
Kamada bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 1.46% increase in the share price the next day.
Here's a look at Kamada's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.02</td>
<td>0.02</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.06</td>
<td>0.04</td>
<td>-0.04</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>10.0%</td>
<td>-0.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709665365_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Kamada were trading at $6.39 as of March 04. Over the last 52-week period, shares are up 49.61%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/KMDA/earnings">To track all earnings releases for Kamada visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Kamada's Earnings

<ul>
<li>Since 2018 Kedrion has had exclusive distribution rights in the US for KEDRAB&#xAE;, a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. &nbsp;</li>
<li>New agreement becomes effective in January 2024 and includes potential expansion of Kedrion's distribution of KEDRAB&#xAE; in additional territories beyond the US &nbsp;</li>
<li>Rabies is a global public health concern that is responsible for more than 59,000 human deaths per year in the world; an estimated 60,000 Americans receive Rabies post exposure prophylaxis each year &nbsp;</li>
<li>Kedrion confirms its commitment to fighting Rabies and other serious and life-threatening diseases and conditions</li>
</ul>
CASTELVECCHIO PASCOLI, Italy, Dec. 7, 2023 /PRNewswire/ --Kedrion Biopharma, a leading global biopharmaceutical company that develops, manufactures and commercializes therapeutic products derived from blood plasma, announces the execution of a binding memorandum of understanding with Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA)), an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB&#xAE; US distribution agreement between the two companies.
KEDRAB&#xAE; is a Human Rabies Immune Globulin (HRIG) developed in partnership with Kamada Ltd. Kedrion started the distribution of this product in the US in 2018.
This new commercial agreement, which begins in January 2024, includes potential expansion of Kedrion's distribution of KEDRAB&#xAE; in additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products by Kamada in Israel.
Ugo Di Francesco, CEO of Kedrion, said, "This agreement marks another relevant milestone in the growth of Kedrion in the US, which remains our most important market. At Kedrion, we firmly believe in the power of our long-term partnership with Kamada to help people who have been exposed to Rabies. This agreement will allow us to continue to serve patients in the US, leveraging the expertise and the extensive know-how we have acquired over the years. Kedrion's commitment to providing relief from conditions requiring hyperimmune plasma-derived therapies remains strong."
"We are thrilled to secure this strategic agreement with Kedrion as it represents our largest commercial agreement since Kamada's inception," said Amir London, CEO of Kamada. "Based on Kedrion's extensive market coverage and on-going success in marketing KEDRAB&#xAE; in the US, as well as the significant market share growth achieved to date, we are confident that the continuation of this partnership maximizes the future growth and value potential of this important product."
Rabies is a serious and life-threatening disease but is easily preventable. It is contracted from the bite of a rabid wild animal – primarily bats, raccoons, skunks and foxes – as well as rabid pets. Human Rabies Immune Globulin is administered at the bite-wound site and is a part of the post exposure prophylaxis (PEP) protocol, along with vaccine, and is recommended when there is an exposure to a rabid or a possibly rabid animal.
Still today, Rabies is a global public threat that causes more than 59,000 human deaths per year in the world. PEP treatment is administered an estimated 60,000 per year each year in the United States.
About KEDRAB&#xAE;
KEDRAB&#xAE; [Rabies Immune Globulin (Human)] is a human rabies immune globulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection in persons of all ages when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.
KEDRAB was approved by the FDA in August 2017. KEDRAB is supplied in single-dose vials containing 2 mL or 10 mL of ready-to-use solution with a nominal potency of 150 IU/mL.

Biotech

Contracts

General

Kedrion Announces An Eight-Year Extension Of The Distribution Agreement With Kamada In The U.S. For Kedrab

WIIM

Kamada shares are trading higher after the company announced a binding memorandum of understanding with Kedrion for the amendment and extension of the KEDRAB U.S. distribution agreement between the parties.

Kamada Announces Binding MOU With Kedrion For The Amendment And Extension Of US Distribution Agreement For KEDRAB; Within First Four Years, Kedrion Will Purchase Minimum Quantities Of KEDRAB With Revenues To Kamada Of $180M

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 500 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $37.93 million which beat the analyst consensus estimate of $37.54 million by 1.06 percent. This is a 17.75 percent increase over sales of $32.22 million the same period last year.

Kamada Q3 EPS $0.06 Beats $0.03 Estimate, Sales $37.93M Beat $37.54M Estimate

AACG

ABOS

ACIC

ACOR

ACTG

AFYA

AGRO

AKTS

AMPS

ASTR

ASUR

ATEX

ATXS

AZTA

BAER

BIOR

BIOX

BWEN

CARA

CELC

CLSD

CPLP

CYCC

DCTH

DFLI

DMAC

DRRX

DXYN

EDBL

ELUT

EYEN

FFIE

FTRE

GEVO

GLAD

GRCL

GRND

HOFV

HROW

HSAI

HSIC

ICAD

ICCC

ICMB

IMCC

JRSH

LICY

LUCD

LUNR

MBRX

MDAI

MITQ

MKFG

MNDY

MVLA

NABL

NVGS

NXGL

OCFT

OMQS

OPAL

OWLT

PLSE

PRSO

RBOT

RELI

ROIV

RVYL

SACH

SALM

SBLK

SKIN

SKYX

SLND

SMTI

SNDL

SOHU

SPRO

TBIO

THMO

TOVX

Earnings Scheduled For November 13, 2023

Health Care

Kamada Announced Multiple Recent Achievements Related To Cytogam, Indicated For The Prophylaxis Of Cytomegalovirus Disease Associated With Transplantation Of Kidney, Lung, Liver, Pancreas, And Heart

Here's the major earnings before the open tomorrow

Kamada GAAP EPS of $0.08, revenue of $42.5M

Kamada (KMDA) has released an update. Kamada Ltd. has announced robust financial results for the first half of 2024, showing an 18% increase in six...

Kamada Ltd. Reports Substantial Growth in 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!



Moving stocks this morning are earnings reports, a stock offering, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Digital Ally (NASDAQ:<a href="https://investorplace.com/stock-quotes/dgly-stock-quote/">DGLY</a>) stock is rocketing more than 107% alongside heavy pre-market trading.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are soaring over 53% with the <a href="https://www.nasdaq.com/press-release/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides">release of its Q2 earnings report</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is surging more than 42% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518494&amp;type=PDF&amp;symbol=CDT&amp;cdn=197541151657f71d6ed19abcc1e0e48e&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=3&amp;formDescription=Initial+statement+of+beneficial+ownership+of+securities&amp;dateFiled=2024-08-13">an investment update</a>.</li>



<li>Nuburu (NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) shares are rising over 26% despite a lack of news this morning.</li>



<li>Jianzhi Education Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is gaining close to 19% even with a <a href="https://www.nasdaq.com/press-release/jianzhi-education-technology-group-company-limited-receives-nasdaq-notification-0">recent delisting notice</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are increasing more than 18% on <a href="https://www.nasdaq.com/press-release/edible-garden-reports-157-increase-gross-profit-fueled-year-over-year-growth-61-cut">strong Q2 earnings</a>.</li>



<li>Ucloudlink (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucl-stock-quote/">UCL</a>) stock is heading over 16% higher with its <a href="https://www.nasdaq.com/press-release/ucloudlink-group-inc-announces-unaudited-second-quarter-2024-financial-results-2024">most recent earnings report</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) shares are jumping 16% with strong early morning trading.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is climbing more than 15% with its <a href="https://www.stocktitan.net/news/SERV/serve-robotics-announces-second-quarter-2024-wqwtqr037uv4.html">Q2 earnings report</a>.</li>



<li>Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) shares are up over 15% after posting <a href="https://www.nasdaq.com/press-release/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-year-over">positive Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is crashing more than 42% after <a href="https://www.nasdaq.com/press-release/tc-biopharm-announces-pricing-20-registered-direct-offering-2024-08-13">pricing a registered direct offering</a>.</li>



<li>Surgepays (NASDAQ:<a href="https://investorplace.com/stock-quotes/surg-stock-quote/">SURG</a>) shares are plummeting over 26% after <a href="https://www.prnewswire.com/news-releases/surgepays-announces-second-quarter-2024-financial-results-302221503.html">reporting a Q2 loss</a>.</li>



<li>Arcadia Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rkda-stock-quote/">RKDA</a>) stock is diving more than 16% after <a href="https://markets.businessinsider.com/news/stocks/rkda-stock-earnings-arcadia-biosciences-for-q2-of-2024-1033684150">missing Q2 EPS estimates</a>.</li>



<li>Ouster (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/">OUST</a>) shares are taking an over 16% beating on <a href="https://www.businesswire.com/news/home/20240813944318/en/Ouster-Reports-Strong-Revenue-and-Margins-for-Second-Quarter-2024">mixed Q2 earnings</a>.</li>



<li>QuickLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/quik-stock-quote/">QUIK</a>) stock is tumbling more than 16% with its <a href="https://www.prnewswire.com/news-releases/quicklogic-reports-41-year-over-year-revenue-growth-for-second-quarter-fiscal-2024-302221555.html">latest earnings release</a>.</li>



<li>Brinker International (NYSE:<a href="https://investorplace.com/stock-quotes/eat-stock-quote/">EAT</a>) shares are sliding over 16% after <a href="https://www.investing.com/news/stock-market-news/brinker-international-stock-tumbles-13-on-q4-earnings-miss-93CH-3570960">posting an earnings miss</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is falling more than 15% after <a href="https://www.stocktitan.net/news/PRTG/portage-biotech-announces-1-for-20-reverse-stock-sficaewojjpr.html">announcing a reverse stock split</a>.</li>



<li>Global E Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/glbe-stock-quote/">GLBE</a>) shares are decreasing over 14% with its <a href="https://www.stocktitan.net/news/GLBE/global-e-reports-second-quarter-2024-1dq5hcfetvn1.html">Q2 earnings report</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 14% without any clear news this morning.</li>



<li>WISeKey (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkey-stock-quote/">WKEY</a>) shares close out our pre-market stock movers down nearly 14% on a <a href="https://www.nasdaq.com/press-release/sealcoin-secures-50-million-investment-commitment-gem-digital-limited-through-0">new investment</a> <a href="https://www.nasdaq.com/press-release/wisekey-partners-venafi-post-quantum-encryption-services-2024-08-14">and partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) just reported results for the second quarter of 2024.<ul><li>Kamada reported earnings per share of 8 cents. This was above the analyst estimate for EPS of 6 cents.</li><li>The company reported revenue of $42.47 million.</li><li>This was 6.98% better than the analyst estimate for revenue of $39.70 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/kmda-stock-earnings-kamada-for-q2-of-2024/">KMDA Stock Earnings: Kamada Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KMDA Stock Earnings: Kamada Beats EPS, Beats Revenue for Q2 2024

Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kamada (KMDA – Research Report) today and set a price target of $11.00. Andrew Fein ...

Buy Rating Affirmed for Kamada on Strong Clinical and Financial Performance

Kamada expands plasma collection operations in Texas with new site in Houston

Comments

Kamada

Vendite allo scoperto

Kamada (NASDAQ:KMDA) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO